NeuroPointDX Email Format
Biotechnology ResearchWisconsin, United States11-50 Employees
NeuroPointDX is a biotechnology research company focused on metabolomics to identify differences in metabolism associated with autism spectrum disorder and other neurological conditions. Through its Stemina Biomarker Discovery division, the firm develops diagnostic approaches that aim to enable earlier detection and more precise treatment options by analyzing small-molecule differences in blood samples from children with ASD. The company is advancing its diagnostic program via the Children’s Autism Metabolome Project (CAMP), a clinical study intended to validate its markers and bring a testing solution to market. Based in Madison, Wisconsin, NeuroPointDX operates within the biotechnology research sector, offering solutions that target clinicians and researchers seeking objective metabolic markers to inform autism assessment and intervention.